$BCRX continues to gain, already up 3% today

Several pharmaceutical businesses have recently seen an increase in their stock value and are among the top gainers. BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) started the week on a green note, and it appears as the trend will continue.

BCRX stock was valued at $16.93 at 05:15 a.m. EST, adding $0.53 to its value and up 3.04%.

BCRX stock performance this week

Stocks ended Monday’s session with a 28% increase, as investors cheered early fourth-quarter sales estimates and very optimistic full-year projections. The company’s market capitalization was $2.4 billion. The total number of shares traded was 2,496,080, close to the average of 2,943,093.

On Tuesday, it maintained its Monday gains, closing at $16.43, up 11.16%, and adding $1.65 to its market capitalization.

The company’s traded volume has climbed to 20,710,158, much greater than the 3,296,207 average. The pharmaceutical company’s market capitalization was $2.95 billion at the time of writing this article.

The BCRX stock lost approximately 18% of its value in the previous week. On January 3, 2022, the stock finished at $14.07, while on Friday, it closed at $11.56.

On the other hand, the stock has risen 83.8% in the last year, outperforming the industry’s loss of 27.9%.

BCRX is rated Overweight (Buy) by the analyst, and his $21 price objective implies a 28% gain in the next 12 months.

Analysts’ Estimate for BCRX FY21 Q4

The pharmaceutical business is predicted to disclose a quarterly loss of $0.32 per share, representing a year-over-year change of +5.9% in its forthcoming report. Revenues are predicted to reach $46.65 million, an increase of 1060.5% over the previous quarter.

Over the previous 30 days, BioCryst’s consensus EPS estimate for the quarter has been revised 7.6% higher to the present level.

On February 23, 2022, it is slated to disclose its FY21 Q4 financial reports.

Performance data for Orladeyo

ORLADEYO’s preliminary net revenue for Q4 2021 is $45.6 million, with $122 million for FY 2021.

ORLADEYO’s net revenue is predicted to more than double in 2022, to no less than $250 million; ORLADEYO is expected to become the market leader in HAE prophylactic therapy, with peak sales of $1 billion, according to the company.

Aside from HAE, BioCryst is testing its oral Factor D inhibitor, BCX9930, in a rare illness called paroxysmal nocturnal hemoglobinuria (PNH). REDEEM-1 and REDEEM-2 are two pivotal studies in which the business is presently recruiting PNH patients.

BCRX is also starting a proof-of-concept basket trial to look into BCX9930 in the indications of C3 glomerulopathy, IgA nephropathy, and primary membranous nephropathy.

Related Posts